Newsbenzinga
Precision BioSciences Says Safety Board Clears Further Dosing In Phase 1/2 PBGENE-DMD Duchenne Trial After No Serious Adverse Events In First Patient
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…